Added to YB: 2025-05-15
Pitch date: 2025-05-14
CHRS [neutral]
Coherus Oncology, Inc.
+75%
current return
Author Info
Steve Wagner provides in-depth analysis of my favorite individual companies. Sign up for the newsletter.
Company Info
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States.
Market Cap
$96.2M
Pitch Price
$0.79
Price Target
N/A
Dividend
N/A
EV/EBITDA
-4.12
P/E
1.95
EV/Sales
1.15
Sector
Biotechnology
Category
value
Coherus BioSciences Q1 2025 Earnings: Transition Complete, But the Proof Still Awaits
CHRS (earnings update): Completed transition from biosimilars to oncology with Udenyca sale ($483M upfront). Loqtorzi for NPC generated $7.3M in Q1 (+15% demand QoQ). Pipeline shows promise: CHS-114 (anti-CCR8) and casdozokitug (IL-27) showing early efficacy. Post-sale: $250M cash, no debt, 2+ year runway. Target $150-200M NPC revenue in 3 years.
Read full article (9 min)